文献速递关节外科

哪些临床与患者因素影响全关节置换术后再入院的国家经济负担?

Which Clinical and Patient Factors Influence the National Economic Burden of Hospital Readmissions After Total Joint Arthroplasty?
PubMed 文献 · Clin Orthop Relat Res · 2017-01-01

基于美国全国再入院数据库2013年前9个月719,394例初次全关节置换术和62,493例90天再入院,分析再入院发生率、支付方构成及与费用相关的患者、临床和医院因素。结果显示THA和TKA的30天再入院率均为4%,90天再入院率分别为8%和7%;再入院住院时长是费用的首要驱动因素,感染、脱位和假体周围骨折等手术相关并发症占THA再入院总费用的59%、占TKA的49%。

要点

  • THA的30天和90天再入院率分别为4%和8%,TKA分别为4%和7%。
  • 再入院住院时长是90天THA和TKA再入院费用的最重要驱动变量。
  • 手术相关并发症(感染、脱位、假体周围骨折)占THA再入院总费用的59%,占TKA的49%。

核心结论

  • 全关节置换术后90天内再入院对美国医疗系统构成巨大经济负担,每年再入院总经济负担约一半为与关节置换手术无关的内科原因,一半为手术相关并发症。

研究设计与样本

  • 使用美国医疗成本与利用项目全国再入院数据库(2006家医院、21个州),基于ICD-9-CM编码识别2013年前9个月719,394例初次全关节置换术和62,493例90天再入院。
  • 将再入院原因分类为手术相关或内科相关,使用数据库提供的费用-收费比计算每例患者90天再入院的连续费用变量,分别对THA和TKA建立一般线性模型,并将支付方、患者、临床和医院因素作为协变量。

主要发现

  • THA的30天和90天再入院率分别为4%(95%CI 4.2%-4.5%)和8%(95%CI 7.5%-8.1%)。
  • TKA的30天和90天再入院率分别为4%(95%CI 3.8%-4.0%)和7%(95%CI 6.8%-7.2%)。
  • 基于III型F统计量(p<0.001)排序,90天THA再入院费用的五个最重要变量依次为住院时长、全患者细化诊断相关组(APR DRG)严重度、再入院类型(内科相关 vs 手术相关)、医院所有权和年龄;90天TKA再入院费用的五个最重要变量依次为住院时长、APR DRG严重度、性别、医院手术量和医院所有权。
  • 调整协变量后,私人保险报销的90天再入院平均费用在THA中比Medicare平均高1324美元(p<0.001),在TKA中比Medicare平均高1372美元(p<0.001)。
  • 全关节置换术后90天内,每年再入院总费用的三分之二由Medicare覆盖;THA术后90天内手术相关并发症(包括感染、脱位和假体周围骨折)合计占美国医疗系统再入院总费用的59%(95%CI 59.1%-59.6%),TKA术后90天内手术相关问题占再入院总费用的49%(95%CI 48.8%-49.6%),其中以感染最为突出。

临床怎么用

  • 作者指出,该全国性研究强调再入院期间的住院时长是主要费用驱动因素,提示医院和医生应在可能范围内进一步优化再入院患者住院的临床路径。
  • 作者指出,因感染、脱位和假体周围骨折再入院的患者费用最高,努力缩短这类再入院的住院时长将对经济负担产生最大影响。
  • 作者指出,需要额外的临床研究来确定在不牺牲医疗质量或可及性的前提下,再入院期间住院时长可缩短的程度(如有)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Affordable Care Act of 2010 advanced the economic model of bundled payments for total joint arthroplasty (TJA), in which hospitals will be financially responsible for readmissions, typically at 90 days after surgery. However, little is known about the financial burden of readmissions and what patient, clinical, and hospital factors drive readmission costs. QUESTIONS/PURPOSES: (1) What is the incidence, payer mix, and demographics of THA and TKA readmissions in the United States? (2) What patient, clinical, and hospital factors are associated with the cost of 30- and 90-day readmissions after primary THA and TKA? (3) Are there any differences in the economic burden of THA and TKA readmissions between payers? (4) What types of THA and TKA readmissions are most costly to the US hospital system? METHODS: The recently developed Nationwide Readmissions Database from the Healthcare Cost and Utilization Project (2006 hospitals from 21 states) was used to identify 719,394 primary TJAs and 62,493 90-day readmissions in the first 9 months of 2013 based on International Classification of Diseases, 9th Revision, Clinical Modification codes. We classified the reasons for readmissions as either procedure- or medical-related. Cost-to-charge ratios supplied with the Nationwide Readmissions Database were used to compute the individual per-patient cost of 90-day readmissions as a continuous variable in separate general linear models for THA and TKA. Payer, patient, clinical, and hospital factors were treated as covariates. We estimated the national burden of readmissions by payer and by the reason for readmission. RESULTS: The national rates of 30- and 90-day readmissions after THA were 4% (95% confidence interval [CI], 4.2%-4.5%) and 8% (95% CI, 7.5%-8.1%), respectively. The national rates of 30- and 90-day readmissions after primary TKA were 4% (95% CI, 3.8%-4.0%) and 7% (95% CI, 6.8%-7.2%), respectively. The five most important variables responsible for the cost of 90-day THA readmissions (in rank order, based on the Type III F-statistic, p < 0.001) were length of stay (LOS), all patient-refined diagnosis-related group (APR DRG) severity, type of readmission (that is, medical- versus procedure-related), hospital ownership, and age. Likewise, the five most important variables responsible for the cost of 90-day TKA readmissions were LOS, APR DRG severity, gender, hospital procedure volume, and hospital ownership. After adjusting for covariates, mean 90-day readmission costs reimbursed by private insurance were, on average, USD 1324 and USD 1372 greater than Medicare (p < 0.001) for THA and TKA, respectively. In the 90 days after TJA, two-thirds of the total annual readmission costs were covered by Medicare. In 90 days after THA, more readmissions were still associated with procedure-related complications, including infections, dislocations, and periprosthetic fractures, which in aggregate account for 59% (95% CI, 59.1%-59.6%) of the total readmission costs to the US healthcare system. For TKA, 49% of the total readmission cost (95% CI, 48.8%-49.6%) in 90 days for the United States was associated with procedure issues, most notably including infections. CONCLUSIONS: Hospital readmissions up to 90 days after TJA represent a massive economic burden on the US healthcare system. Approximately half of the total annual economic burden for readmissions in the United States is medical and unrelated to the joint replacement procedure and half is related to procedural complications. CLINICAL RELEVANCE: This national study underscores LOS during readmission as a primary cost driver, suggesting that hospitals and doctors further optimize, to the extent possible, the clinical pathways for the hospitalization of readmitted patients. Because patients readmitted as a result of infection, dislocation, and periprosthetic fractures are the most costly types of readmissions, efforts to reduce the LOS for these types of readmissions will have the greatest impact on their economic burden. Additional clinical research is needed to determine the extent to which, if any, the LOS during readmissions can be reduced without sacrificing quality or access of care.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Kurtz SM, Lau EC, Ong KL, et al. Which Clinical and Patient Factors Influence the National Economic Burden of Hospital Readmissions After Total Joint Arthroplasty? Clin Orthop Relat Res. 2017. PMID: 28108823. doi:10.1007/s11999-017-5244-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。